Not only that, but the efficacy means those patients are going home. Cured.
Not slowly dying and clogging up the hospital system and draining it of funds.
These savings is why hospital purchasers and administrators will be focused on remestemcel-L and looking very favourably indeed at the next MSB products to be approved.
Accelerated Approval? Bring it on!
2024 Here we go again., page-665
-
- There are more pages in this discussion • 279 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
90.5¢ |
Change
0.020(2.26%) |
Mkt cap ! $1.033B | |||
| Open | High | Low | Value | Volume |
| 88.5¢ | 95.0¢ | 88.0¢ | $5.610M | 6.115M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 317774 | 90.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 91.5¢ | 23500 | 2 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |